• 1
    Robinson AS, Vreysen MJ, Hendrichs J & Feldmann U (2009) Enabling technologies to improve area-wide integrated pest management programmes for the control of screwworms. Med Vet Entomol 23 (Suppl 1), 17.
  • 2
    Robinson DS (1993) Interleukin-5, eosinophils and bronchial hyperreactivity. Clin Exp Allergy 23, 13.
  • 3
    Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R, Muller WA, Hicklin DJ, Bohlen P & Dejana E (2001) Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 97, 16791684.
  • 4
    Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P & Dejana E (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100, 905911.
  • 5
    Robinson SD & Hodivala-Dilke KM (2011) The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 23, 630637.
  • 6
    Serini G, Napione L, Arese M & Bussolino F (2008) Besides adhesion: new perspectives of integrin functions in angiogenesis. Cardiovasc Res 78, 213222.
  • 7
    Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE & Ellis LM (2001) Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15, 12391241.
  • 8
    Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE & Kalluri R (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275, 2134021348.
  • 9
    Brooks PC, Clark RA & Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569571.
  • 10
    Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G & Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 11571164.
  • 11
    Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA & Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270, 15001502.
  • 12
    Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ & Cheresh DA (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6, 30563061.
  • 13
    Wayner EA, Orlando RA & Cheresh DA (1991) Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol 113, 919929.
  • 14
    Mahabeleshwar GH, Feng W, Phillips DR & Byzova TV (2006) Integrin signaling is critical for pathological angiogenesis. J Exp Med 203, 24952507.
  • 15
    Mahabeleshwar GH, Feng W, Reddy K, Plow EF & Byzova TV (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101, 570580.
  • 16
    Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G & Bussolino F (1999) Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18, 882892.
  • 17
    Beauvais DM, Burbach BJ & Rapraeger AC (2004) The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 167, 171181.
  • 18
    Beauvais DM, Ell BJ, McWhorter AR & Rapraeger AC (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691705.
  • 19
    Beauvais DM & Rapraeger AC (2003) Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res 286, 219232.
  • 20
    Beauvais DM & Rapraeger AC (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 123, 37963807.
  • 21
    Rapraeger AC (2013) Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αVβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J, in press.
  • 22
    Delafontaine P, Song YH & Li Y (2004) Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24, 435444.
  • 23
    Robinson TJ & Stranc MF (1970) The anatomy of the medial canthal ligament. Br J Plast Surg 23, 17.
  • 24
    Kim S, Bell K, Mousa SA & Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156, 13451362.
  • 25
    Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB & Mignatti P (1998) Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 141, 16591673.
  • 26
    Bazzoni G & Dejana E (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84, 869901.
  • 27
    Kooistra MR, Corada M, Dejana E & Bos JL (2005) Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 579, 49664972.
  • 28
    Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oosthuyse B, Dewerchin M et al. (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147157.
  • 29
    Dejana E, Orsenigo F & Lampugnani MG (2008) The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121, 21152122.
  • 30
    Liao F, Li Y, O'Connor W, Zanetta L, Bassi R, Santiago A, Overholser J, Hooper A, Mignatti P, Dejana E et al. (2000) Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 60, 68056810.
  • 31
    Sakamoto Y, Ogita H, Hirota T, Kawakatsu T, Fukuyama T, Yasumi M, Kanzaki N, Ozaki M & Takai Y (2006) Interaction of integrin alpha(v)beta3 with nectin. Implication in cross-talk between cell-matrix and cell–cell junctions. J Biol Chem 281, 1963119644.
  • 32
    Alghisi GC, Ponsonnet L & Ruegg C (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4, e4449.
  • 33
    Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K & Dellian M (2002) Inhibition of the alpha-V integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 86, 788795.
  • 34
    Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ & De Waal RM (1997) Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71, 320324.
  • 35
    Sepp NT, Li LJ, Lee KH, Brown EJ, Caughman SW, Lawley TJ & Swerlick RA (1994) Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J Invest Dermatol 103, 295299.
  • 36
    Stupack DG & Cheresh DA (2003) Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene 22, 90229029.
  • 37
    Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM & Cheresh DA (2001) Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155, 459470.
  • 38
    Avraamides CJ, Garmy-Susini B & Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8, 604617.
  • 39
    Peterson JE, Kulik G, Jelinek T, Reuter CW, Shannon JA & Weber MJ (1996) Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by src. J Biol Chem 271, 3156231571.
  • 40
    Borges E, Jan Y & Ruoslahti E (2000) Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 275, 3986739873.
  • 41
    Ott VL & Rapraeger AC (1998) Tyrosine phosphorylation of syndecan-1 and -4 cytoplasmic domains in adherent B82 fibroblasts. J Biol Chem 273, 3529135298.
  • 42
    Clemmons DR & Maile LA (2005) Interaction between insulin-like growth factor-I receptor and alphaVbeta3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs. Mol Endocrinol 19, 111.
  • 43
    Ling Y, Maile LA, Badley-Clarke J & Clemmons DR (2005) DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 280, 31513158.
  • 44
    Maile LA & Clemmons DR (2002) Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. J Biol Chem 277, 89558960.
  • 45
    Mitola S, Brenchio B, Piccinini M, Tertoolen L, Zammataro L, Breier G, Rinaudo MT, den Hertog J, Arese M & Bussolino F (2006) Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism 1. Circ Res 98, 4554.
  • 46
    Mattila E, Auvinen K, Salmi M & Ivaska J (2008) The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling. J Cell Sci 121, 35703580.
  • 47
    Nakamura Y, Patrushev N, Inomata H, Mehta D, Urao N, Kim HW, Razvi M, Kini V, Mahadev K, Goldstein BJ et al. (2008) Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell–cell adhesions in endothelial cells. Circ Res 102, 11821191.
  • 48
    Shigematsu S, Yamauchi K, Nakajima K, Iijima S, Aizawa T & Hashizume K (1999) IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr J 46 (Suppl), S5962.
  • 49
    Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC & Sanderson RD (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 24492457.
  • 50
    Theocharis AD, Skandalis SS, Tzanakakis GN & Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 39043923.
  • 51
    Manon-Jensen T, Itoh Y & Couchman JR (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 38763889.
  • 52
    Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC & Lawley TJ (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99, 683690.
  • 53
    McQuade KJ, Beauvais DM, Burbach BJ & Rapraeger AC (2006) Syndecan-1 regulates alpha(v)beta(5) integrin activity in B82L fibroblasts. J Cell Sci 119, 24452456.
  • 54
    Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, Puzon-McLaughlin W, Lafuente EM, Boussiotis VA, Shattil SJ et al. (2006) Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr Biol 16, 17961806.
  • 55
    Takagi J, Petre BM, Walz T & Springer TA (2002) Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110, 599511.